Top in GI: Infliximab retreatment; short bowel syndrome guidance - Healio

After 26 weeks of retreatment with infliximab, 35% of patients with Crohn’s illness achieved remission, according to caller data.

Researchers said determination was nary important quality betwixt rates of objective remission successful patients who antecedently discontinued infliximab owed to nonaccomplishment of effect vs. intolerance. It was the apical communicative successful gastroenterology past week.

The American Gastroenterological Association precocious published signifier recommendations for the absorption of abbreviated bowel syndrome. Source: Adobe Stock. 

Another apical communicative covered the American Gastroenterological Association’s clinical signifier recommendations for the absorption of abbreviated bowel syndrome.

Read these and much apical stories successful gastroenterology below:

Infliximab retreatment results successful remission successful 35% of patients with Crohn’s disease

After antecedently discontinuing infliximab, 35% of patients with Crohn’s illness achieved remission astatine 26 weeks with cause retreatment, according to a survey published successful The American Journal of Gastroenterology. Read more.

AGA offers 12 champion signifier recommendations for managing abbreviated bowel syndrome

The AGA has released a objective signifier update and adept reappraisal connected the characterization and absorption of patients with abbreviated bowel syndrome, which precocious was published successful Clinical Gastroenterology and Hepatology. Read more.

Q&A: Updated ACG monograph provides guidance for GI attraction during pregnancy, postpartum

The ACG has published a supplement to The American Journal of Gastroenterology with updated recommendations for the absorption of gastrointestinal disorders successful patients who are large oregon successful the postpartum period. Read more.

Obeticholic acerb flops successful signifier 3 proceedings for compensated NASH-related cirrhosis

Obeticholic acerb failed to show superiority to placebo for improving fibrosis successful patients with compensated cirrhosis owed to nonalcoholic steatohepatitis successful a signifier 3 trial, according to an Intercept Pharmaceuticals property release. Read more.

Obeticholic acerb yields less deaths, liver transplants successful superior biliary cholangitis Patients who received obeticholic acerb for superior biliary cholangitis experienced greater transplant-free endurance compared with outer power patients, according to probe published successful Gastroenterology. Read more.